Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Factor H" patented technology

Factor H is a member of the regulators of complement activation family and is a complement control protein. It is a large (155 kilodaltons), soluble glycoprotein that circulates in human plasma (at typical concentrations of 200–300 micrograms per milliliter). Its principal function is to regulate the alternative pathway of the complement system, ensuring that the complement system is directed towards pathogens or other dangerous material and does not damage host tissue. Factor H regulates complement activation on self cells and surfaces by possessing both cofactor activity for the Factor I mediated C3b cleavage, and decay accelerating activity against the alternative pathway C3-convertase, C3bBb. Factor H exerts its protective action on self cells and self surfaces but not on the surfaces of bacteria or viruses. This is thought to be the result of Factor H having the ability to adopt conformations with lower or higher activities as a cofactor for C3 cleavage or decay accelerating activity. The lower activity conformation is the predominant form in solution and is sufficient to control fluid phase amplification. The more active conformation is thought to be induced when Factor H binds to glycosaminoglycans (GAGs) and or sialic acids that are generally present on host cells but not, normally, on pathogen surfaces ensuring that self surfaces are protected whilst complement proceeds unabated on foreign surfaces.

Kidney active fusion proteins and methods of treatment using the same

PCT designated stageWO2026135714A1Connective tissue peptidesPeptide/protein ingredientsSegmental glomerulosclerosisRenal glomerulus
Described herein are fusion proteins which include factor H functional domains and may include VHH domains and integrin binding domains, and the use of such fusion proteins in methods of treatment of focal segmental glomerulosclerosis.
Owner:ALEXION PHARMACEUTICALS INC

Compositions and methods for treating complement-mediated diseases

ActiveCN115976105BDiseasePharmacy medicine
The present invention relates to compositions and methods for treating complement-mediated diseases. Provided are recombinant vectors having an expression cassette comprising a modified human factor H (hfH) gene, wherein the hfH gene encodes a hfH protein variant comprising SCR1-4, 19-20, and one or more of: SCR7, SCR17, and / or SCR18. Also provided are pharmaceutical compositions comprising the vectors and their use in treating AMD and / or other complement-related diseases.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Sialylated human factor h protein for treatment of paroxysmal nocturnal hemoglobinuria

PendingAU2025213816A1Paroxysmal AFThrombocyte aggregation
The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.
Owner:ELEVA GMBH

Methods of treating ocular diseases using engineered polypeptides comprising complement factor h and factor h-like protein domains

PendingUS20260201001A1DiseaseGeographic atrophy
Methods of treating ocular diseases such as age-related macular degeneration may include the administration of peptides comprising complement factor H and factor H-like protein domains to reduce an amount of geographic atrophy in a subject in need thereof. These methods may be administered by intraocular, intervascular or subcutaneous injection.
Owner:CHARACTER BIOSCIENCES INC

AAV variant for the treatment of complement imbalance

PendingJP2026518295AOrganic active ingredientsSenses disorderGeographic atrophyTransgene
Recombinant AAV (rAAV) comprising a variant adeno-associated virus (AAV) capsid and a transgene encoding a human factor H variant is provided. Also provided are a method for delivering the transgene to the retina, and a method for treating dry age-related macular degeneration and geographic atrophy secondary to age-related macular degeneration by contacting retinal cells with rAAV. The variant AAV capsid protein may contain a peptide insertion ("heterogeneous peptide" or "peptide insertion") of about 7 to 20 amino acids within the GH loop of the capsid protein, preferably within the surface-exposed region of the GH loop, compared to the corresponding parental AAV capsid protein.
Owner:4D MOLECULAR THERAPEUTICS INC

Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases

The present application provides methods of treating a complement-mediated disease in a human individual, comprising administering to the individual an effective amount of a fusion protein comprising i) an antibody moiety that specifically binds to human C5 and ii) a Factor H (FH) or functional fragment thereof. The complement-mediated disease can be, for example, paroxysmal nocturnal hemoglobinuria (PNH) syndrome, C3 glomerulopathy (C3G), IgA nephropathy (IgAN), and thrombotic microangiopathy secondary to systemic lupus erythematosus (SLE-TMA).
Owner:KIRA PHARMACEUTICALS (US) LLC

Treatment of anca-associated vasculitis

PendingCN122341383AComplement S-ProteinAntiendomysial antibodies
Compounds, compositions, and methods are provided for treating ANCA-associated vasculitis (AAV) in patients of need. The method includes administering an effective amount of a composition comprising a fusion protein construct comprising: an antibody that specifically binds to complement protein 3d (c3d), and two complement modulatory peptides, each of the complement modulatory peptides comprising a bioactive fragment of factor H.
Owner:AKEBIA THERAPEUTICS INC